Hyperparathyroidism; Secondary, Renal
Conditions
Keywords
cinacalcet, secondary hyperparathyroidism, calcimimetics, CKD-MBD
Brief summary
1. To evaluate achievement ratio of iPTH,Calcium and phosphorus after taking Cinacalcet HCL in hemodialysis subjects with mild, moderate and severe SHPT; 2. To explore the impact of Cinacalcet HCL using on the combined use of drugs; 3. To explore the difference of patients who continued or discontinued Cinacalcet HCL in real-world period from 33rd to 52nd week.
Interventions
DRUGCinacalcet HCl
Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.
Sponsors
Kyowa Kirin China Pharmaceutical Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
CKD Hemodialysis Patients with SHPT
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
\- Parents/guardians must sign informed consent; Must be males or females whose age are 18 to 75 years old; Clinical diagnosis of chronic kidney disease on maintenance hemodialysis with secondary hyperparathyroidism; iPTH must be equal or higher than 300Pg/ml; Must not have received Calcimimetics(for example, Cinacalcet) within 6 months prior to enrollment; Must have been on maintenance hemodialysis 3 times weekly (TIW) for at least 3 months(12 weeks) prior to enrollment and must be expected to remain on hemodialysis for the duration of the study; Over 2-year life expectancy.
Exclusion criteria
\- Hypocalcemia \[Corrected serum calcium level less than 2.1mmol/L(8.4mg/dL); History of gastrointestinal bleeding or peptic ulcer disease and possibility of deterioration or recurrence; Severe heart disease; Epilepsy risk or history of epilepsy; Hypersensitivity to Cinacalcet; Drug abuse/addiction; Plan to receive renal transplantation within 52 weeks; Pregnant or lactating women; Pregnancy plan within 1 years, or no guarantee on taking effective contraceptive measures within 1 year after enrollment; Participated in other clinical trials within 4 weeks prior to enrollment; Received parathyroidectomy within 24 weeks prior to enrollment; Investigator judgment that patients are not suitable to enroll.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Compared with baseline data, the proportion of subjects reaching iPTH target at 20th week | 20 weeks | blood test |
| Compared with baseline data, the proportion of subjects reaching iPTH target at 32nd week | 32 weeks | blood test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compared with baseline data, the proportion of patients with ≥ 30% reduction in iPTH level at 32nd week | 32 weeks | blood test |
| The proportion of patients once reaching iPTH target during 1st~32nd week | 32 weeks | blood test |
| The proportion of patients once reaching iPTH target during 33rd~52nd week | 52 weeks | blood test |
| Compared with baseline data, the change of Ca × P at 20th week | 20 weeks | blood test |
| Compared with baseline data, the change of Ca × P at 32nd week | 32 weeks | blood test |
| Compared with baseline data, the change of alkaline phosphatase (ALP) at 20th week | 20 weeks | blood test |
| Compared with baseline data, the change of alkaline phosphatase (ALP) at 32nd week | 32 weeks | blood test |
| Compared with baseline data, the change of fibroblast growth factor 23(FGF23) at 20th week | 20 weeks | blood test |
| Compared with baseline data, the change of fibroblast growth factor 23(FGF23) at 32nd week | 32 weeks | blood test |
| Compared with baseline data, the adjustment (type or amount) of calcium agents at 20th week | 20 weeks | medication evaluation |
| Compared with baseline data, the adjustment (type or amount) of calcium agents at 32nd week | 32 weeks | medication evaluation |
| Compared with baseline data, the adjustment (type or amount) of phosphate binders at 20th week | 20 weeks | medication evaluation |
| Compared with baseline data, the adjustment (type or amount) of phosphate binders at 32nd week | 32 weeks | medication evaluation |
| Compared with baseline data, the adjustment (type or amount) of vitamin D and its analogues at 20th week | 20 weeks | medication evaluation |
| Compared with baseline data, the adjustment (type or amount) of vitamin D and its analogues at 32nd week | 32 weeks | medication evaluation |
| Compared with baseline data, the proportion of patients reaching Ca & P target simultaneously at 32nd week | 32 weeks | blood test |
| Compared with baseline data, the adjustment (type or amount) of diphosphonic acid salts at 32nd week | 32 weeks | medication evaluation |
| Compared with the data at 32nd week, the proportional change of patients reaching iPTH target at 52nd week who continue Cinacalcet treatment during 20-week real world period | 52 weeks | blood test |
| Compared with the data at 32nd week, the proportional change of patients reaching iPTH target at 52nd week who discontinue Cinacalcet treatment after 20-week real world period | 52 weeks | blood test |
| Compared with the data at 32nd week, the proportional change of patients reaching Ca target at 52nd week who continue Cinacalcet treatment after 20-week real world period | 52 weeks | blood test |
| Compared with the data at 32nd week, the proportional change of patients reaching Ca target at 52nd week who discontinue Cinacalcet treatment after 20-week real world period | 52 weeks | blood test |
| Compared with the data at 32nd week, the proportional change of patients reaching P target at 52nd week who continue Cinacalcet treatment after 20-week real world period | 52 weeks | blood test |
| Compared with the data at 32nd week, the proportional change of patients reaching P target at 52nd week who discontinue Cinacalcet treatment after 20-week real world period | 52 weeks | blood test |
| Compared with the data at 32nd week, the proportional change of patients reaching Ca × P target at 52nd week who continue Cinacalcet treatment after 20-week real world period | 52 weeks | blood test |
| Compared with the data at 32nd week, the proportional change of patients reaching Ca × P target at 52nd week who discontinue Cinacalcet treatment after 20-week real world period | 52 weeks | blood test |
| The dose change of calcium agents which were used by patients for chronic kidney disease-mineral and bone disorder(CKD-MBD) treatment during 20-week real world period | 20 weeks | medication evaluation |
| The dose change of phosphate binders which were used by patients for chronic kidney disease-mineral and bone disorder(CKD-MBD) treatment during 20-week real world period | 20 weeks | medication evaluation |
| The dose change of vitamin D and its analogues which were used by patients for chronic kidney disease-mineral and bone disorder(CKD-MBD) treatment during 20-week real world period | 20 weeks | medication evaluation |
| The dose change of diphosphonic acid salts which were used by patients for chronic kidney disease-mineral and bone disorder(CKD-MBD) treatment during 20-week real world period | 20 weeks | medication evaluation |
| The reasons of patients discontinuing Cinacalcet in 20-week real world | 20 weeks | List presentation |
| Compared with baseline data, the adjustment (type or amount) of diphosphonic acid salts at 20th week | 20 weeks | medication evaluation |
| Compared with baseline data, the proportion of patients with ≥ 30% reduction in iPTH level at 20th week | 20 weeks | blood test |
Countries
China
Outcome results
None listed